BioWorld

Nov. 9, 2006

View Archived Issues

Pipex Completes Reverse Merger, Reports Positive Coprexa Data

Pipex Therapeutics Inc. merged with the shell company Sheffield Pharmaceuticals Inc., disclosing at the same time positive data from the pivotal Phase III trial with its lead candidate Coprexa for Wilson's disease. (BioWorld Today) Read More

Solstice Adds $85M Through Series B Round And Debt Deal

Read More

Bradley Licenses U.S. Rights To BioSante's Bio-E-Gel Product

Read More

Catalyst Grosses $20.1M In IPO To Support Addiction Studies

Read More

Other News To Note

Read More

Clinic Roundup

Read More